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We tested a new in vivo hematopoietic stem cell (HSC) transduction/selection approach in rhesus 26 
macaques using HSC-tropic, integrating, helper-dependent adenovirus vectors (HDAd5/35++) designed 27 
for expression of human globin in red blood cells (RBCs) to treat hemoglobinopathies. We show that 28 
HDAd5/35++ vectors preferentially transduce HSCs in vivo after intravenous injection into G-29 
CSF/AMD3100-mobilized animals, and that transduced cells return to the bone marrow and spleen. The 30 
approach was well tolerated and activation of proinflammatory cytokines that is usually associated with 31 
intravenous adenovirus vector injection, was successfully blunted by pre-treatment with dexamethasone 32 
in combination with IL-1 and IL-6 receptor blockers. Using our MGMTP140K-based in vivo selection 33 
approach, -globin+ RBCs increased in all animals with levels up to 90%. After selection, the percentage of 34 
-globin+ RBCs declined most likely due to an immune response against human transgene products. Our 35 
biodistribution data indicate that -globin+ RBCs in the periphery were mostly derived from mobilized 36 
HSCs that homed to the spleen. Integration site analysis revealed a polyclonal pattern and no genotoxicity 37 
related to transgene integrations. This is the first proof-of-concept study in nonhuman primates that in 38 
vivo HSC gene therapy could be feasible in humans without the need for high-dose chemotherapy 39 


















Autologous HSC gene therapy for hemoglobinopathies has shown promising effective cures 1-4. Despite 49 
the encouraging clinical results, current ex vivo HSC gene therapy protocols have multiple shortcomings 50 
throughout the process: i) harvesting HSCs by leukapheresis or bone marrow aspiration (invasive 51 
procedure), ii) myeloablation by chemotherapy (high-dose chemotherapy-related side-effects, infectious 52 
disease complications, conditioning-associated genotoxicity), iii) in vitro HSC culture and transplantation 53 
(loss of HSC pluripotency during extended ex vivo culture; need for specialized facility/staff). iv) the cost 54 
of the approach. Because of cost and technical complexity, it is unlikely that ex vivo protocols will be 55 
widely applicable, specifically in developing countries where the greatest demand for hemoglobinopathy 56 
therapy lies.  57 
We are working on an approach for transduction of HSCs in vivo using helper-dependent adenovirus 58 
vectors systems (HDAd5/35++). So far, we have published safety and efficacy data obtained in mice 5-16.  59 
Our approach involves the mobilization of HSCs from the bone marrow by granulocyte colony-stimulating 60 
factor (G-CSF) and the short-acting CXCR4 antagonist Plerixafor/AMD3100. While mobilized HSCs circulate 61 
at high numbers in the periphery, HDAd5/35++ vectors are injected intravenously 17. Mobilization of HSCs 62 
is critical for in vivo transduction because in the bone marrow they are surrounded by extracellular stroma 63 
proteins 18, and are not accessible to gene transfer vectors 12.  HDAd5/35++ vectors are easy to 64 
manufacture at high yields, can carry a payload of 35kb, and efficiently transduce primitive, quiescent 65 
HSCs through CD46 12. The vectors’ affinity to CD46 has been increased 19 to allow for in vivo HSC 66 
transduction without significant vector uptake by hepatocytes 20,21. Random integration of HDAd5/35++ 67 
vectors is mediated by an activity-enhanced Sleeping Beauty transposase (SB100x) 22. To expand 68 
transduced HSCs, we currently use an in vivo selection mechanism based on a mutant O6-methylguanine-69 
DNA methyltransferase (mgmtP140K) gene that confers resistance to O6-BG/BCNU (O6-70 










BG/BCNU administered intraperitoneally with an interval of 2 weeks, transgene marking in PBMCs was 72 
usually increased to >90% 16. We have shown that our approach resulted in phenotypic correction in 73 
mouse disease models of thalassemia intermedia 14, Sickle Cell Disease, murine hemophilia A 15, and in 74 
the reversion of spontaneous cancer 25.  75 
  76 
The biodistribution and function of CD46 in mice and humans are different 26. In humans, CD46 is present 77 
on all nucleated cells, while the expression of the mouse CD46 orthologue is restricted to the testis. For 78 
our in vivo HSC transduction studies, we therefore used human CD46 transgenic mice. These mice carry 79 
400kb of the human CD46 locus 27 and express the protein in a pattern similar to humans 28. It remains 80 
however unclear whether human CD46 is able to trigger intracellular signaling in this heterologous 81 
transgenic mouse model. Furthermore, innate and adaptive immune responses initiated by intravenous 82 
HDAd5/35++ injection might not be adequately reflected in the mouse model. The physiological 83 
similarities of the human and macaque hematopoietic systems make rhesus macaques (Macaca mulatta) 84 
a better model for a potential clinical translation of our in vivo HSC gene therapy approach. The expression 85 
pattern of CD46 in rhesus macaques is similar to humans with a notable exception that CD46 is found on 86 
red blood cells (RBCs) 29,30. Intravenous injection of CD46-targeting Ad5/35 31 and Ad35 vectors 32 into 87 
NHPs did not result in efficient transduction of normal tissues, most likely because of the low CD46 density 88 
on differentiated cells 33 and inaccessibility due to localization in epithelial junctions 34.  89 
 90 















Development of an in vivo HSC transduction approach for NHPs 97 
HSC targeting through CD46 with HDAd5/35++ vectors.  We have recently reported that CD46 is 98 
expressed at a higher level on human CD34+ cells compared to other mononuclear cells in the bone 99 
marrow and peripheral blood 12 suggesting that CD46 also has (a yet unknown) function in HSCs.  In 100 
Fig.S1A, we show uniform high expression of CD46 on primitive rhesus HSCs (CD34+/CD45RA-/CD90+ cells) 101 
35. In vitro transduction of human and rhesus CD34+ cells with a GFP-expressing HDAd5/35++ vector 102 
yielded higher percentages of GFP-positive cells (50-65%) in CD34+/CD45RA-/CD90+ cells than in the pool 103 
of CD34+ cells, most likely due to higher CD46 density (Figs.S1B-D). This study suggests that HDAd5/35++ 104 
vectors are suitable for in vivo HSC transduction in rhesus macaques.  105 
Our goal was to test HDAd5/35++ vectors for gene therapy of hemoglobinopathies based on promising 106 
studies performed in CD46-transgenic mouse models for thalassemia and Sickle Cell Disease 10,14,36. Four 107 
rhesus macaques were treated successively (Table 1). Based on the data from the N=1 studies, we 108 
modified the experimental design for the next animal (Table 2).  All vectors tested contained a cassette 109 
for random chromosomal integration of the human -globin gene (HBG1) and the human mgmtP140K gene. 110 
We are using two vectors to achieve transgene integration): i) a transposon vector containing the 111 
therapeutic cargo sequence flanked by SB100x inverted repeats and frt sites and ii) the transposase vector 112 
(HDAd-SB) to provide SB100x and Flpe (for transposon circularization) in trans 22,37 (Fig.1A). NHPs#1 and 3 113 
received a vector containing the human -globin gene under the control of the 4.3kb “short” -globin LCR 114 
for erythroid-specific expression. NHP#4 received a vector containing a ~25kb long -globin LCR to 115 
maximize -globin expression levels 36.   116 
NHP#2 was injected with a HDAd5/35++ vector designed for targeted integration of the -globin cassette 117 










due to an erroneous tacrolimus overdose (given through a gastric catheter). Our long-term data are 119 
therefore only from NHP#1, 3 and 4.  120 
 121 
HSC mobilization and timing of HDAd5/35++ injection. CD46 on rhesus RBCs can sequester HDAd5/35++-122 
virions thus serving as a vector trap following intravenous administration. This is supported by an in vitro 123 
study (Fig.S2). In an attempt to mitigate this issue by increasing the vector dose, we established an HSC 124 
mobilization regimen that would involve two waves of mobilization. At the peak of each, we would then 125 
intravenously inject the HDAd5/35++ vector thereby doubling the vector dose applied to the animal 126 
(Fig.S3A). We speculated that this would increase the number of in vivo transduced HSCs.  To find the 127 
optimal time point for HDAd5/35++ injection, we measured hourly the number of HSCs in peripheral blood 128 
of G-CSF/AMD3100-mobilized animals (between 4 and 12 hours after AMD3100 injection). For each 129 
peripheral blood sample, we determined the percentage of CD34+/CD45RA-/CD90+ cells in PBMCs by flow 130 
cytometry (Fig.S3B, D) and the percentage of progenitor colony-forming cells in CD34+ cells (as a functional 131 
HSC parameter) (Fig.S3C). These tests showed a robust HSC mobilization with a peak at ~8 hours after 132 
AMD3100 injection. Based on this, we developed the mobilization/HDAd5/35++ injection regimen shown 133 
in Fig.1B.  134 
In our in vivo HSC transduction studies, using the two-wave mobilization/HDAd injection protocol, 135 
mobilization efficacy was in the range of 18-70x103 CD34+/CD45RA-/CD90+ cells per ml peripheral blood 136 
at the time of vector injection (Fig.1C).   137 
 138 
Prophylaxis for cytokine responses: A major risk factor with intravenous administration of adenovirus 139 
vectors is the activation of the innate immune system 38,39. A hallmark and causative factor of the innate 140 
immune response is the elevation of proinflammatory cytokines and chemokines, in particular IL-1 and IL-141 










triggered serum IL-6 levels greater than 35,000 pg/ml and was accompanied by lethal acute toxicity 39. We 143 
previously showed that pretreatment with dexamethasone blunted cytokines responses in mice 12.  Here, 144 
we pretreated NHP#1 with dexamethasone and the anti-IL6R monoclonal antibody tocilizumab 145 
(Figs.2A,B). This regimen was not sufficient to completely suppress the release of IL-6 and TNF which 146 
peaked at 6 hours after vector dosing. Further addition of the IL-1 blocker anakinra almost completely 147 
blunted cytokine responses associated with intravenous HDAd5/35++ vector administration at a total 148 
dose of 3.2x1012vp/kg in NHPs#2 and 3. In NHP#4, the route of anakinra administration was changed from 149 
intravenous to subcutaneous, which is clinically more accepted. Furthermore, formulating HDAd in a 150 
buffer that did not contain glycerol and giving an IV saline bolus injection after infusion of HDAd5/35++ 151 
prevented hypotension and nausea (see Methods). 152 
Immunosuppression: In contrast to ex vivo HSC gene therapy protocols that involve myeloablation/-153 
conditioning, in our in vivo approach, recipients of the therapy are fully immunocompetent. In our studies, 154 
we therefore had to suppress adaptive immune responses against non-rhesus transgene products 155 
expressed from the HDAd5/35++ vectors (human -globin, human mgmtP140K, SB100x, Flpe). In NHP#1 we 156 
used a combination of daily tacrolimus, sirolimus, and MMF. However, this approach led to drug-related 157 
toxicities and weight loss in the animal so that NHPs#2-4 received only tacrolimus or 158 
tacrolimus+MMF/abatacept (Table 2).    159 
 160 
Efficacy  161 
HDAd5/35++ vector clearance from serum and PBMCs. The number of vector genomes per ml serum was 162 
measured by qPCR using mgmtP140K or -globin-specific primers (Fig.S4A). At 2 hours after intravenous 163 
injection of 1.6x1012 vp/kg, vector genomes per ml serum were in the range of 6-17 x 106 in NHP#2, 3, and 164 
4. By 10 hours, the vast majority of vector genomes had been cleared from the serum. There was a long 165 









early after HDAd5/35++ injection showed a peak with ~4 vector copies per cell at ~6 hours (Fig.S4B). 167 
Vector signals declined by day 7 to below 1 copy per cell, most likely due to the natural turnover of 168 
differentiated blood cells and loss of episomal vector DNA.   169 
 170 
Preferential in vivo transduction of HSCs.  A more detailed VCN analysis at day 7 (day 3 for NHP#2), 171 
including total bone marrow mononuclear cells (MNCs) and bone marrow CD34+ cells demonstrated 172 
preferential in vivo transduction of CD34+ HSCs (Fig.3A). The VCN in blood and bone marrow cells 173 
correlated with mRNA levels for mgmtP140K relative to GAPDH mRNA (Fig.3B). To estimate the percentage 174 
of in vivo transduced HSCs, we plated CD34+ cells (isolated on day 7 from the bone marrow of NHPs#1, 3, 175 
and 4) and measured the VCN in individual progenitor colonies. Vector DNA was detectable in 55% of 176 
colonies (reflecting the in vivo transduction rate of HSCs) (Fig.3C). The vector copy in colonies ranged from 177 
0.05 to 6 copies per cell, with the majority of colonies having around 0.5 copies. HDAd5/35++ genomes 178 
are episomal and are lost during cell division 12. This explains VCNs below 1.0 in the pool of cells from a 179 
given colony (Fig.3C).  VCN was analyzed in colonies at 4, 6 and 16 weeks after in vivo transduction (Fig.3D). 180 
Unexpectedly, the VCN declined over time.   181 
 182 
-globin expression. -globin expression in peripheral RBCs was measured by i) flow cytometry after 183 
intracellular staining with a (cross-reacting) anti-human -globin antibody in Nuclear Red-negative cells. 184 
ii) HPLC of RBC lysates that can separate 2-, 1-, 1-, and 2-globin chains. iii) qRT-PCR for human -185 
globin mRNA (expressed as the percentage of -globin mRNA to rhesus 1-globin mRNA).  186 
In NHP#1, -globin became detectable by flow cytometry of peripheral RBCs after week 2 (Fig.4A). After 187 
the third cycle of O6BG/BCNU treatment, the percentage of -globin+ RBCs climbed to 90%, remained 188 
stable for one month, and then declined to ~75% by week 23 (the endpoint of the study). The -globin 189 










decline observed after the peak at week 16 (Fig.4B). HPLC data agreed with this kinetic (Figs.4C, S5). At 191 
the peak, -globin was 8% of rhesus 1-globin chains.  192 
Notably, NHPs#3 and 4 received a less intense in vivo selection and immunosuppression regimen (see 193 
Table 2).  Overall, the kinetics of -globin marking in peripheral RBCs was similar in these animals, with a 194 
sharp increase after the completion of the third O6BG/BCNU selection cycle with peak levels of 48% and 195 
57% -globin+ RBCs for NHPs#3, and 4 respectively (Fig.4D). -globin marking then declined, reaching 196 
stable levels at ~10%.  197 
The HDAd5/35++ vector injected into NHP#4 contained the long -globin LCR, which conferred higher -198 
globin expression levels, as reflected by a 3- to 4-fold higher MFI (Fig.4E) and significantly higher 199 
percentages of human - to rhesus 1-globin chains measured by HPLC (Fig.4F).     200 
The levels and kinetics of -globin mRNA in RBCs roughly followed the pattern of -globin protein chains 201 
with an increase by in vivo selection (Fig.S6).  Interestingly, in NHPs# 3 and 4, -globin mRNA levels did not 202 
decline as seen on the protein level.  203 
We also measured mRNA levels of the other transgene, human mgmtP140K, which is under the control of 204 
the EF1 promoter (Fig.5A, S7).  In PBMCs, in vivo selection increased the level of mgmtP140K mRNA in 205 
NHPs #1, 3, and 4. As seen with globin, the increase in mgmtP140K mRNA levels was followed by a 5-10-206 
fold decline. mgmtP140K mRNA in BM MNCs and CD34+ cells did not increase by in vivo selection.  207 
We hypothesized that a critical factor that played a role in the decline of globin marking after the peak 208 
were immune responses against cells that express transgene products, specifically human MGMTP140K.  As 209 
shown for NHP#3, the decline in -globin+ RBCs coincided with a rise in serum anti-human MGMT IgG 210 
antibodies (Figs.5A,B). The decline could temporarily be reversed with more intense immunosuppression 211 
including MMF and abatacept indicating that an immune response was responsible for the decline.  Note 212 










(Fig.5C). Human and rhesus HBG1 proteins are 98% identical, and no profound anti-human HGB1 humoral 214 
immune response was detected (Fig.5D).  215 
In summary, the globin expression analysis in RBCs shows that it is possible to achieve meaningful 216 
marking rates with in vivo selection and immunosuppression. As shown in NHP#1, it can reach 90% -217 
globin+ RBCs and globin levels greater 10% of rhesus 1-globin levels. In contrast to peripheral RBCs 218 
and PBMCs, in bone marrow MNCs and CD34+ cells, the VCN and level of mgmtP140K mRNA were low and 219 
declining over time. This implies that peripheral globin+ RBCs are derived from HSCs that do not reside 220 
in the bone marrow.  221 
 222 
The spleen as a homing site for in vivo transduced HSCs. During necropsy of NHPs#3 and 4 performed ~6 223 
months after HDAd5/35++ injection, blood was washed out from the circulation, and tissues were 224 
collected. The VCN per cell was measured by qPCR. The highest VCNs (2-5 copies per cell) were found in 225 
the spleen, followed by liver, lung, and gall bladder (Fig.6A). Analysis of a control animal that was not 226 
mobilized and only intravenously injected with HDAd5/35++ (twice 1.6x1012vp/cell) (Fig.6A “NHP-Co) 227 
presented detectable vector DNA only in spleen (0.06 copies/cell) and liver (0.03 copies/cell), levels that 228 
were 100-fold lower than in NHPs#3 and 4. This indicates that transduced cells detected in the spleen are 229 
derived from mobilized HSCs that returned to the spleen and not from direct virus transduction. 230 
Furthermore, VCNs from NHP#2 (euthanized at day 3) show homing to spleen (VCN: 1.47) and bone 231 
marrow (VCN: 0.3). VCNs in spleen were 4- to 7-fold higher for NHP#3, and 4, which underwent in vivo 232 
selection, indicating that transduced cells expanded over time in the spleen as a result of in vivo selection. 233 
Notably, scant to mild mixed extramedullary hematopoiesis was seen on spleen samples collected at 234 
necropsy (see Pathology Report in Suppl. Information).  235 
Pools of splenocytes from NHP#3 and 4 were sub-fractioned by magnetic cell isolation using CD34, CD14, 236 










copies/cell in NHP#3 and 4, respectively) compared to 0.19 and 0.44 vector copies in splenic CD34-238 
negative cells, including CD14+, CD20+, and CD4+/8+ cells. In contrast, the VCN in bone marrow was barely 239 
above the detection limit. A similar distribution in tissues was seen based on the mgmtP140K mRNA (Fig.6C). 240 
Transduced splenocytes were also detected on tissue sections by immunofluorescence for human MGMT, 241 
with about 25% MGMT-positive cells on a given spleen section being positive (Fig.6E, S8A). Sparse MGMT-242 
positive cells were found in liver and lung sections, which did not resemble hepatocytes or alveolar 243 
epithelial cells (Fig.S8B). Importantly, no vector genomes or mgmtP140K mRNA were found in reproductive 244 
organs in all four animals.    245 
 246 
Contribution of splenic HSCs to hematopoiesis:  In agreement with published literature 43, the number of 247 
CD34+ cells per cm3 tissue was 10-fold lower for the spleen than bone marrow (Fig.S9A). CD34+ cells 248 
isolated from rhesus spleen were functional as shown by their capacity to expand and differentiate in 249 
vitro. Their ability to form progenitor colonies was comparable to that of CD34+ cells purified from bone 250 
marrow (Fig.S9B). When subjected to erythroid differentiation (ED) in liquid culture 44,45, erythroblasts 251 
developed, and at later stage (day 10 of ED), efficient rhesus hemoglobin (HBA and HBF) synthesis and 252 
enucleation was observed (Figs.S9C and D). Importantly, the percentage of -globin+ enucleated cells and 253 
the -globin MFI were greater in cells differentiated from CD34+ cells of NHP#4 compared to an untreated 254 
animal. This could be due to added human -globin production in erythroblasts derived from gene-255 
modified CD34+ cells. The latter is supported by the presence of human HBG mRNA in NHP#4 samples 256 
(Fig.S9D).  Together, these data indicate that in vivo transduced splenic HSCs have the potential to 257 
contribute to hematopoiesis and be the source of -globin+ RBCs in peripheral blood.     258 
 259 










Pathology/Histopathology. During mobilization and HDAd5/35++ injection procedures, all animals were 261 
BAR (bright, alert, reactive) without elevation of body temperature or loss of appetite. While we observed 262 
significant body weight loss in NHP#1 due to an intensive immunosuppressive regimen with tacrolimus, 263 
sirolimus, and MMF, in addition to the in vivo selection (BCNU dose: 30mg/m2) (Fig.7A), the overall 264 
physical condition of the other animals was good and no remarkable, treatment-related clinical side 265 
effects were listed in the audited Pathology/Histopathology reports (see Suppl. Information).  266 
Hematology. Most hematological and biochemical parameters (CBC and blood chemistry) were within 267 
normal range, including the liver transaminases GPT, GOT (Figs.7B, S10). Noteworthy are the following 268 
abnormalities: i) Temporary thrombocytopenia was observed between days 1 and 4 which was followed 269 
by a compensatory increase in platelet counts (Fig.7C). ii) Elevation in D-dimer concentrations to levels 270 
~2.5g/ml (but below the critical 5g/ml value) was observed starting immediately after HDAd5/35++ 271 
injection and lasting for 3 days (Figs.7D). Other coagulation parameters (fibrinogen, prothrombin time, 272 
partial thromboplastin time) were unremarkable (Fig.S10-part 5). iii) The concentration of complement 273 
factor C3 increased, reaching peak values (100-150ng/ml) at 6 hours after HDAd5/35++ injection (Fig.7E). 274 
iv) As expected, G-CSF/AMD3100 mobilization resulted in an increase in white blood cell counts 275 
(lymphocytes, neutrophils, monocytes, basophils), from day 0 to day 4 (Figs.7F, S10-part 3). Notably, 276 
neutrophils contain pro-inflammatory cytokines that can be released during senescence. To counteract 277 
this, we gave anakinra also on days 1 and 2 after HDAd5/35++ injection (see Methods). v) lymphocyte 278 
counts were low due to immunosuppression (Fig.S10-part 3).  279 
We also measured by flow cytometry the percentage of lineage-positive (CD3+, CD14+ and CD20+) cells in 280 
PBMCs and bone marrow mononuclear cells (Fig.S11). In PBMCs, a transient decline in the percentage of 281 
CD3+ and CD20+ cells from day -2 to weeks 3-4) and slight increase in CD14+ cells were noticeable in all 282 
four animals.  The number of bone marrow CD34+ cells transiently declined after O6BG/BCNU treatment 283 










Adaptive immune responses: In spite of immune-suppression, humoral immune responses (serum IgG 285 
and IgM) were activated. Anti-human MGMT and anti-human -globin serum antibody titers for selected 286 
animals were shown in Fig.5. The full set of data can be found in Figs.S12 and S13. Antibody responses 287 
against HDAd5/35++ virions (Fig.S14), SB100x, and Flpe (Fig.S15) were transient, most likely due to short-288 
term presence of the corresponding antigens. In future studies, it needs to be tested whether 289 
immunosuppression (e.g. by tacrolimus + MMF) is needed to prevent adaptive immune responses against 290 
the transiently expressed SB100x transposase (fish) and Flpe recombinase (E.coli). Clearly, to avoid 291 
immune responses in our upcoming NHP studies, HDAd5/35++ vectors should contain only rhesus 292 
transgenes 46. 293 
In vivo selection: In our studies, in vivo selection with O6BG/BCNU resulted in an increase of transgene-294 
marked cells with acceptable hematopoietic and the extramedullary toxicity. These safety data are in 295 
agreement with previous studies in mice, dogs, non-human primates, and humans involving the 296 
transplantation of ex vivo lentivirus vector transduced HSCs and low doses of methylating agents such as 297 
O6BG/BCNU and the clinically approved drug temozolomide 23,24,47,48  298 
SB100x-mediated integration. SB100x and Flpe are expressed from an episomal vector (HDAd5/35++-SB) 299 
that will be lost during cell division. While Flpe and SB100x mRNA was detectable at day 3 in CD34+ cells, 300 
levels of these mRNAs sharply declined by day 8 and were undetectable by week 4 post-transduction 301 
(Fig.S16A). The kinetics of mRNA expression in PBMCs was similar, with a peak around day 1 and loss by 302 
week 4 (Fig.S16B).  303 
The distribution of integration sites over the rhesus genome in splenocytes of NHPs#3 and 4 is shown in 304 
Figs.8A,B. The vast majority of integrations were within intergenic (62.4/57.6%) and intronic regions 305 
(33.4/38.7%) for NHPs#3 and 4, respectively. The integration was random without preferential integration 306 
in any given window of the whole rhesus genome. No integration within or near any proto-oncogene was 307 










found. This SB100x-mediated integration pattern is in an agreement with previous studies 12,16,49-52. 309 
Notably, the VCN in bone marrow MNCs at necropsy was too low for integration site analysis.  310 
Furthermore, we performed genome-wide RNA-Seq on spleen RNA from NHP#4 to assess effects on the 311 
transcriptome. We found modestly altered expression of only 53 genes (Figs.8C-E). None of these genes 312 
was proto-oncogenic or related to cancer pathways. This indicates that SB100x and O6BG/BCNU 313 
treatments do not exert changes in gene expression in a 6-months study.   314 
 315 
Discussion  316 
Here, we show that our new in vivo HSC transduction/selection approach is safe in rhesus macaques and 317 
yields human -globin+ RBCs for 6 months, i.e. the length of the study. Long-term -globin marking levels 318 
(80, 7, and 11% for NHPs#1, 3, and 4, respectively), reached in our study, would be therapeutic in patients 319 
with hemoglobinopathies.  320 
 Our studies suggest that CD46 is a suitable receptor to target primitive HSCs. Other than CD46-transgenic 321 
mice, NHPs appear to be the only other adequate large animal model for preclinical studies with CD46-322 
interacting HDAd5/35++ vectors.  Canine 53 and pig CD46 are not recognized by these vectors. A major 323 
limitation of NHPs is however that, unlike humans, rhesus erythrocytes possess CD46 on their surface 30, 324 
and therefore cause unspecific sequestration/loss of intravenously injected HDAd5/35++ vector particles. 325 
On the other hand, recent data by Hemminki et al. indicate that adenovirus binding to erythrocytes is 326 
reversible 54. The slow (bi-phasic) serum clearance of vector genomes (Fig.S4), together with our previous 327 
observation that binding of ligands, including HAd5/35++, to CD46 results in shedding of the extracellular 328 
domain of CD46 55, could indicate that this observation is correct. However, it is unknown whether 329 










injected high vector doses in two cycles on consecutive days. (Notably, HDAd5/35++ vectors can be easily 331 
produced at high yields and low costs.) 332 
 333 
A major focus of this study was to assess the safety of our approach. As is known, intravenous injection of 334 
serotype 5-adenovirus vectors is associated with transaminitis 38,39. We designed our HDAd5/35++ vector 335 
to avoid transduction by using short fiber shafts that block hepatocyte transduction. So, liver function 336 
parameters in our NHP studies remained within the normal range.  To minimize any side effect from 337 
cytokine release, animals received a short course of a combination of dexamethasone, tocilizumab, and 338 
anakinra, all FDA-approved drugs and currently being used in the clinic to prevent or treat cytokine release 339 
in CAR T cell therapies.  With this triple drug prophylaxis regimen, infusion of high HDAd5/35++ doses 340 
(total 3.2x1012 vp/kg) was well tolerated and there were no clinical side effects.  Notable deviations from 341 
normal hematological parameters were (G-CSF-triggered) leukocytosis, mild transient complement 342 
activation and increase in D-dimers without any symptoms. In addition, there was a brief (2 to 4 days) 343 
decrease in platelets which was likely multifactorial.   344 
Because of recent reports of rare myeloid malignancies associated with lentivirus vector integration in 345 
clinical trials 56, we paid specific attention to potential genotoxic effects in the context of SB100x-346 
transposase integration and the mgmtP140K-based selection systems. In genome-wide integration site and 347 
transcriptome studies, we confirmed random integration without clonal dominance and minimal changes 348 
in the mRNA profile due to integration into exons.  This integration pattern is, theoretically, safer than 349 
that of lentivirus vectors which show a preference for actively transcribed genes. Clearly, the risk of 350 
genotoxicity cannot be ignored and has to be studied more carefully based on longitudinal integration site 351 











If in vivo selection (O6BG + 102030mg/m2 BCNU) and an immunosuppression (sirolimus+tacrolimus+ 354 
MMF) regimen were implemented in NHP#1, -globin marking of peripheral RBCs reached 90% after the 355 
third round of in vivo selection. Based on RBC HPLC and mRNA data, the level of -globin chains was 8% 356 
of rhesus 1-globin chains. However, the combination of in vivo selection with this intensive 357 
immunosuppression regimen resulted in body weight loss. Thus, subsequent animals (NHPs#3 and 4) 358 
received only tacrolimus and MMF, and we also reduced the third dose of BCNU to 20mg/m2. With this 359 
regiment, -globin marking peaked at ~50% after in vivo selection, with a subsequent decline that levelled 360 
out at a stable marking rate of ~10% -globin+ RBCs. This decline was most likely due to an immune 361 
response against human transgene products, specifically human MGMTP140K. Immune responses could 362 
result in a loss of transduced (marked) cells or also a down-regulation of expression at the levels of 363 
translation as recently shown in rAAV gene therapy studies 57. The latter could explain the discrepancy 364 
between declining RBC marking and increasing -globin mRNA levels in RBCs, specifically in NHPs#3 and 365 
4.  -globin levels in RBCs were higher with a “long” ~26kb -globin LCR driving -globin expression 366 
compared to a 4.3kb LCR version. Notably, the “long” LCR has the capacity of reducing position effects of 367 
integration 13.  368 
Measurement of vector genome copies confirmed that HDAd5/35++ vectors preferentially transduced 369 
mobilized HSCs in the periphery. At day 7, after vector injection, 30-55% of colony-forming CD34+ cells in 370 
the bone marrow were positive for vector DNA by qPCR. However, in all animals, the VCN in bone marrow 371 
mononuclear cells (MNCs) and CD34+ cells declined regardless of in vivo selection. A similar tendency was 372 
seen for bone marrow mgmtP140K mRNA levels. This observation was in conflict with -globin marking in 373 
RBCs and mgmtP140K mRNA expression in PBMCs. Consequently, bone marrow HSCs cannot be the major 374 
source for genetically modified cells in the periphery. Vector DNA and RNA analysis in other tissues 375 
pointed toward a contribution of splenic HSCs to hematopoiesis and transgene-expressing peripheral 376 










that was also reflected by 25% MGMT-positive splenocytes found by immunofluorescence analyses. We 378 
postulate that the high VCN/mgtmP140K expression in the spleen was the result of i) mobilized, transduced 379 
HSCs efficiently returning and surviving in the spleen and ii) an expansion by O6BG/BCNU selection. Data 380 
supporting the first claim come from the finding that intravenous HDAd5/35++ injection into a non-381 
mobilized rhesus macaque resulted in only minimal transduction of spleen (Fig.6A, “NHP-Co”), which is in 382 
agreement with previously published biodistribution data in NHPs after injection of Ad5/35++ 31 and Ad35 383 
vectors 32. The second claim is based on the finding that the VCN in spleen in NHP#2 (day 3, no in vivo 384 
selection) is lower than in NHPs#1, 3, 4 (6 months, with in vivo selection). Furthermore, we hypothesize 385 
that transduced splenic HSCs contribute to peripheral blood cells, which is more evident in gene-modified 386 
RBCs compared to PBMCs (because RBC numbers in peripheral blood are 1000-fold higher than PBMC 387 
numbers). To support our hypothesis, we subjected CD34+ cells, isolated from NHP#4 at 6 months, to in 388 
vitro erythroid differentiation. We showed a higher percentage of -globin+ erythroid cells and a higher 389 
MFI of -globin per cell than in control setting with CD34+ cells from a non-transduced rhesus.  The number 390 
of splenic CD34+ cells isolated from 1cm3 spleen was at least 10-fold lower than that isolated from a similar 391 
volume of a bone marrow MNC pellet. Therefore, the contribution of splenic HSCs to differentiated blood 392 
cells (including -globin+ RBCs) should be correspondingly less.  393 
Transduced cells (based on VCN and immunofluorescence) were also found in liver/gallbladder and lung. 394 
Because of technical difficulties to isolate these cells, it is not clear whether they have HSC function. 395 
Notably, there were no remarkable pathological/histopathological alterations in these organs.  396 
 397 
In contrast to mice, where we observed comparably high VCNs (~3.5 copies per cell) in spleen, bone 398 
marrow and PBMCs (see Fig.S17), in NHPs we found a decline of VCN and mgmtP140K mRNA in in vivo 399 
transduced HSCs that returned to the bone marrow. We believe the most likely explanation for this finding 400 










Notably, the spleen is thought to be immune-privileged due to the presence of large numbers of 402 
immunosuppressive and immune-tolerizing cells 58.  403 
 404 
Publications of HSC trafficking and hematopoiesis after mobilization with different agents are sparce 43,59. 405 
Homing of transplanted HSC is relatively well studied in myeloablated mice and NHPs 60,61. It is thought 406 
that intravenously injected HSCs are not selectively attracted to the bone marrow and spleen but initially 407 
are randomly distributed in tissues 62. Only in the bone marrow and spleen, HSCs survive longer than 48 408 
hours because of the specific micro-environment constituted by β1 and α4 integrins and chemokines, 409 
specifically the CXCR4/SDF-1 pathway 63. The ability to mark mobilized HSCs in vivo by HDAd5/35++ vector 410 
transduction could help studying their fate and improve bone marrow homing.   411 
 412 
While our approach has the potential to greatly simplify HSC gene therapy in humans, it currently has 413 
shortcomings. The first is related to the intravenous injection of viral particles which results in vector 414 
sequestration by blood components and by the reticulo-endothelial system of the liver and spleen.  This, 415 
in turn, triggers innate toxicity and limits target cell transduction. Second, the level of stable HSC 416 
transduction is low, in part because it necessitates the co-infection of two vectors, the transposon vector 417 
and transposase vector.  Reaching therapeutic marking rates therefore requires in vivo HSC selection with 418 
low-dose methylating drugs. 419 
Our current efforts to address these shortcomings and further test our approach in NHPs include: i) HSC 420 
mobilization using a one-day regimen with truncated GRO-  and AMD3100 7. This will reduce leukocytosis 421 
and cytokine release from mobilized neutrophiles. A mobilization regiment without G-CSF would also be 422 
more appropriate for patients with Sickle Cell Disease. ii) Targeting HDAd vectors to another receptor that 423 
is present on primitive HSCs to increase transduction and, in the case of NHPs, prevent RBC sequestration. 424 










also address the issues of pre-existing anti-Ad5 antibodies in humans and innate toxicity triggered by Ad5 426 
penton or hexon proteins64-66. iii) Directing more transduced HSCs to the bone marrow than to the spleen, 427 
because the bone marrow is the major contributor to blood cells under physiological conditions.  Potential 428 
ways to achieve this include short-term overexpression expression of cxcr4 on mobilized HSCs 67 or 429 
treatment with nicotinamide  68. iv) Focus on genome editor-based approaches (Base or Prime Editors) 430 
that would capitalize on intrinsic, disease background related mechanism for in vivo expansion of edited 431 
HSCs and progenitors without vector integration, and that would require only one HDAd vector 69.  432 
 433 
In summary, we showed clear evidence of successful in vivo HSC transduction; based on VCN, -globin 434 
mRNA, mgmtP140K mRNA, and -globin protein levels as well as a response of these parameter to 435 
O6BG/BCNU in vivo selection. This together with the good safety profile suggests that in vivo HSC gene 436 
therapy could be feasible in humans upon further improvements, some of which are outlined above. We 437 
believe that our approach will be more efficient in humans than in rhesus macaques because i) vector 438 
sequestration by RBCs will not have a critical impact on in vivo HSC transduction and bone marrow 439 
homing, ii) immune responses against human transgene products will be absent, and iii) higher -globin 440 
expression levels are expected in patients where the pathologic background will generate a selective 441 
advantage for the transduced cells. 442 
 443 
 444 
Materials and Methods 445 
HDAd5/35++ vectors. HDAd-SB, HDAd-mgmt/GFP, HDAd--globin-hu-mgmtP140K and HDAd-long-LCR--446 










Animals: Three male and two female rhesus macaques (Macaca mulatta) from the Oregon National 448 
Primate Research Center were used for the studies (see Table 1). The studies were performed by the 449 
WaNPRC Research Support Team. All experiments were conducted in accordance with the institutional 450 
guidelines set forth by the University of Washington. The studies were approved by the University of 451 
Washington IACUC (Protocol No. 3108-04). After implantation of an intravenous catheter, animals were 452 
housed individually.  453 
Antibiotics: CEFTAZIDIME/TAZICET (Hospira, Inc): 150mg/kg daily, intravenous (IV), start day of surgery, 454 
continued through study as long as tether is in); FLUCONAZOLE (Northstar Rx): 50mg- flat dose per animal, 455 
IV, start on D-5 per os (PO), semil in die-once daily (SID); ACYCLOVIR (AuroMedics Pharma): 10mg/kg, IV, 456 
Start on D-5 SID  457 
Mobilization: FILGRASTIM/G-CSF/NEUPOGEN (Amgen): 50mcg/kg, SQ, start SID on D-5 afternoon, daily 458 
SID in PM through D0; AMD3100/Plerixafor (Calbiochem) (5mg/kg, subcutaneously (SQ) SID MIDNIGHT 459 
on D-1 and D0 (doses are given at midnight the mornings before HDAd5/35++ dosing at 8am. 460 
Cytokine prophylaxis: DEXAMETHASONE (Fresenius Kabi USA: 4mg/kg, First dose IV SID 2pm on D-2, two 461 
doses each days -1 and 0, ANAKINRA/KINERET (Swedish Orphan Biobivitrium): 50mg/dose- flat dose, 2 462 
doses each SQ D-1 and D0 (1h before and 6 hrs after HDAd5/35++ injection), one dose each D1 and D2; 463 
TOCILIZUMAB/ACTEMRA (Genentech Inc) (8mg/kg, 2 doses IV each D-1 and D0 (1h before and 6 hrs after 464 
HDAd injection), diluted infusions IV (50ml each). 465 
HDAd5/35++ vector infusion: For infusion, HDAd preps are thawed, diluted with PBCs (room 466 
temperature) and infused within 30-60min after preparation. A low dose (5x1010vp/kg in 5ml of PBS is 467 
given over 10 min followed by the therapeutic dose (usually 1.6x1012vp/kg) in 20ml of PBS infused over 468 
20minutes   469 
Anti-emetic/hypotension prophylaxis: Lactated Ringer Solution/LRS BOLUS: 8ml/kg, IV SID D-1 and D0, 470 










give prior to HDAd5/35++ infusions; ONDANSETRON (Hikma Pharmaceutricals): 2mg/kg, IV SID D-1 and 472 
D0, give prior to HDAd5/35++ infusions 473 
Immunosuppression: TACROLIMUS/PRPGRAF (Astellas Pharma): 0.02mg/kg to start, then adjust to get 474 
blood level ~15ng/ml, start SQ BID (bis in die-twice a day) on D-5 morning, continue through study. 475 
Mycophenolate Mofetil Hydrocloride/MMF/CellCept (Genentech): 40mg/kg, start D1, 20mg/kg PO BID; 476 
ORENCIA/ ABATACEPT (Brystol-Myers Squibb): 60mg/dose- flat dose, IV doses on D-2, 0, 2, 7, 14  477 
In vivo selection: O6-Benzylguanine (Sigma) and Carmustine/BCNU (Sigma) were made fresh for each 478 
injection. First, O6BG (120mg/m2) is infused IV over 15 to 20 minutes (flow rate ~600 mL/hour). BCNU is 479 
given ~30-45 minutes after the end of O6BG infusion. The BCNU doses were 10, 20, and 30mg/m2. O6BG 480 
infusion (120mg/m2) is repeated 7-8 hours after the end of the first infusion. Neutrophil counts decreased 481 
after each round of O6BG/BCNU treatment. The subsequent dose of O6BG/BCNU was therefore given only 482 
after neutrophil counts recovered (2-4 weeks).  483 
Necropsy: Animals were sedated and then injected IV with an overdose of pentobarbital. Blood was 484 
flushed out from the body with 5 liters of PBS using an external perfusion pump.  485 
 486 
Detection of cell surface markers by flow cytometry. A list of antibodies used can be found in Fig.S18.  487 
 488 
The following Methods can be found in the Suppl. Information section: HDAd5/35++ production, CD34+ 489 
cell culture; Isolation of CD34+ cells from spleen and bone marrow; In vitro erythroid differentiation of 490 
rhesus CD34+ cells, HDAd5/35++ vectors; Colony-Forming Cell (CFC) Assay; Detection of cell surface 491 
markers by flow cytometry; Detection of human -globin expression by intracellular staining;  Globin HPLC; 492 
Measurement of vector copy number; Real-time reverse transcription PCR; Cytometric Bead Array; Anti-493 
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Figure legends 731 
Figure 1. Injection of HDAd5/35++ vectors for -globin gene addition into mobilized rhesus macaques. 732 
A) Vector structure. globin gene addition is achieved through the SB100x transposase system consisting 733 
of a transposon vector with IRs and frt sites flanking the expression cassette and a second vector (HDAd-734 
SB) that provides the SB100x and Flpe recombinase in trans 22. Animals received the SB100x/FLPe-735 
expressing HD-SB vector together with a -globin expressing transposon vector (1:1 ratio). HDAd--globin-736 
mgmt
P140K
: The transposon cassette for random integration consists of a mini -globin LCR/promoter for 737 
erythroid specific expression of human -globin (HBG1, 76-Ile variant). The -globin 3'UTR serves for mRNA 738 
stabilization in erythroid cells. The -globin expression unit is separated by a chicken globin HS4 insulator 739 
from a cassette for human mgmtP140K expression from a ubiquitously active PGK promoter. In HDAd-long-740 
-globin-hu-mgmt
P140K
, the human -globin gene is under the control of a 21.5kb -globin LCR (chr11: 741 
5292319-5270789), a 1.6kb -globin promoter (chr11: 5228631-5227023) and a 3’HS1 region (chr11: 742 
5206867-5203839) also derived from the -globin locus 13. B) Timing of G-CSF, AMD3100 and HDAd5/35++ 743 
vector injection. C) Numbers of primitive (CD34+/CD45RA-/CD90+) HSCs in peripheral blood. HDAd5/35++ 744 
vectors were injected at the two peaks of mobilization. Vector dosing in NHP#1 was conservative 745 
(0.51.6x1012 vp/kg). The other animals were dosed with two times 1.6x1012vp/kg except NHP#3. The 746 
low second HDAd5/35++ dose in NHP#3 was based on a worrisome neutrophil count received shortly 747 
before the second HDAd5/35++ injection. Later, this count was found to be erroneous. The time of 748 
HDAd5/35++ injection is indicated as “0h” correspondingly at day -1 and day 0. After this time point, blood 749 
samples were analyzed at 2, 6, and 9 hours on days -1 and day 0 and then, on days 1, 2, 3, and 7.   750 
 751 
Figure 2. Serum levels of pro-inflammatory cytokines after HDAd5/35++ injection. NHP#1 received 752 










anakinra. In NHP#4, anakinra was given subcutaneously. The graphs also show the HDAd5/35++ vector 754 
dose injected.   A) IL-6 levels measured by cytometric bead array. B) TNFlevels measured by CBA. TNF 755 
was not detectable in NHP#2.  IL-2, IL-4, IL-5, and IFN were not detectable by CBA in all animals.  756 
 757 
Figure 3. Vector genomes in HSCs. A) Vector Copy Number (VCN) per cell at day 7 (NHPs#1, 2, 4) and day 758 
3 (NHP#2) after the second HDAd5/35++ injection. Genomic DNA was isolated from PBMCs, total bone 759 
marrow mononuclear cells (BM-MNCs) and bone marrow CD34+ cells and subjected to qPCR. B) Day 7 760 
(NHPs#1, 2, 4) and day 3 (NHP#2) mgmtP140K mRNA levels in different cell fractions. C) Vector copies per 761 
cell in individual progenitor colonies. CD34+ cells from day 7 bone marrow of NHP#3 were plated for 762 
progenitor colony assay. Colonies were picked after 12 days of culture and subjected to qPCR for vector 763 
genomes. D) Percentages of vector DNA-positive colonies in NHPs#1, 3, and 4 at the indicated time points.  764 
 765 
Figure 4. -globin expression in RBCs. A-C) NHP#1 data. A) Percentages of -globin-positive RBCs in 766 
peripheral blood measured by flow cytometry. RBCs don’t contain nuclei and are negative for nuclear red 767 
(NucRed) staining. The time and dose of O6BG/BCNU selection are indicated. O6BG was given twice at 768 
120mg/m2.  The BCNU doses were 10, 20, and 30mg/m2. B) -globin mean fluorescence intensity (MFI) in 769 
peripheral blood samples. C) Percentage of -globin chains relative to rhesus 1-globin measured by HPLC.  770 
D) -globin expression in RBCs of NHPs#3 and 4. Note that the aggressive immunosuppressive regimen 771 
(Tacrolimus, Sirolimus, MMF) and in vivo selection (10, 20, 30 mg/m2 BCNU, two weeks apart) performed 772 
in NHP#1 caused critical body weight loss and was therefore not repeated in the subsequent animals. 773 
Shown are percentages of -globin-positive RBCs in peripheral blood measured by flow cytometry. E and 774 
F) Level of -globin expression from “short” LCR (NHPs#1,3) and “long” LCR (NHP#4). E) MFI data. Left 775 










HPLC: -globin to rhesus 1-globin chains are shown for NHP#1 (wk19), NHP#3 (wk18), and NHP#4 (wk15) 777 
* p<0.05.       778 
 779 
Figure 5. Serum IgG and IgM antibody titers. A-B) Correlation of mgmtP140K mRNA expression in PBMCs, 780 
immunosuppression (A) and anti-human MGMT serum antibodies (B) in NHP#3. Note that mgmtP140K 781 
mRNA levels increased after the third round of in vivo selection and the implementation of a more 782 
stringent immunosuppressive regimen (tacrolimus, MMF, abatacept). Increase in MGMT expression 783 
coincided with an elevation of serum antibodies, i.e. a stronger immune response, which in turn could 784 
have eliminated transduced PBMCs causing the decline in human mgmtP140K mRNA levels. C) anti-human 785 
MGMT titers in NHP#1, the animal that received more stringent immunosuppression, in comparison to 786 
NHP#3.  B) Anti-human HBG1 titers in NHP#4 as a representative example.  787 
 788 
Figure 6. Vector biodistribution in other tissues. A) VCN. NHP#1, 3, and 4 were euthanized at ~6 months 789 
after HDAd5/35++ injection and tissues were analyzed. NHP#2 was euthanized at day 3 after HDAd5/35++ 790 
injection. NHP-Co (black bars) was a rhesus macaque that was not mobilized but injected with 791 
HDAd5/35++ (twice 1.6x1012vp/kg) and euthanized at day 3.  B) VCN in bone marrow and spleen 792 
subfractions of NHPs#3 and 4. C) Relative level of mgmtP140K mRNA in tissues. D) Spleen section from 793 
NHP#3 stained with antibodies against human MGMT (green).  The scale bar is 20 m. Controls are shown 794 
in Fig. S9. 795 
 796 
 797 











Figure 8. Genome and transcriptome analysis in NHPs #3 and 4. A) Chromosomal distribution of 800 
integration sites in splenic CD34+ cells harvested at ~6 months. The integration sites are marked by vertical 801 
red lines. GW04-T1 = NHP#3, GW05-T2=NHP#4.  B)  Upper panel: Integration pattern in rhesus genomic 802 
windows. The number of integrations overlapping with continuous genomic windows and randomized 803 
mouse genomic windows and size was compared. This shows that the pattern of integration is similar in 804 
continuous and random windows. Maximum number of integrations in any given window was not more 805 
than 3; with one integration per window having the higher incidence. Lower panel: Integration sites were 806 
mapped to the genome and their location with respect to genes was analyzed. Shown is the percentage 807 
of integration events that occurred 1kb upstream transcription start sites, 3’UTR of exons, protein coding 808 
sequences, introns, 3’UTRs, 1kb downstream from 3’UTR, and intergenic. C) mRNA from total blood cells 809 
of NHP#3 was subjected to RNA-Seq performed by Omega Bioservices.  Shown are genes with altered 810 
mRNA expression (log2 fold change) ranked based on their p value. D) Volcano plot of all mRNA data. E) 811 





















Table 1: Information on animal weight, age, source, and study duration. ONPRC: Oregon National 824 
Primate Research Center.  825 
Animal ID Age (years) Weight (kg) Gender Source Study 
duration 
NHP#1 A17284 5.6 11.5 M ONPRC 08/12/19 - 
01/06/20 
NHP#2 A19237 5.5 9.0 M ONPRC 01/26/20 - 
01/31/20 
NHP#3 A19238 4.4 6.0 M ONPRC 03/01/20 - 
09/08/20 
NHP#4 A20141 8.0 5.8 F ONPRC 01/11/21 – 
07/21/21 







Table 2: Information on HDAd vectors, doses, cytokine prophylaxis, immunosuppression, and in vivo 831 
selection. NHP#2 was injected with a HDAd5/35++ vector designed for targeted integration of the g-globin 832 
cassette into a safe genomic harbor (PMID: 31494053). However, NHP#2 had to be euthanized on day 3 833 
after HDAd injection due to an erroneous tacrolimus overdose (given through a gastric catheter). NHP-Co 834 
was added to assess the affect of mobilization on vector biodistribution. SB100x: activity-enhanced 835 
Sleeping Beauty transposase; Flpe: activity-enhanced Flp recombinase; LCR: b-globin locus control region; 836 
SC: subcutaneous; PO: per os – oral; IM: intramuscular  837 
 838 








In vivo selection 
O6BG/BCNU (mg/m2) 








wk 4: 120/10 
wk 6: 120/20 
wk 8: 120/30 



















(SC, wk21-24)  
wk 4: 120/10 
wk 8: 120/20 
wk 13: 120/20 









(SC, d0-wk3)  
wk 3: 120/10 
wk 7: 120/20 
wk 9: 120/20 
wk 18: 120/20 








































































eTOC Synopsis  
We have developed an in vivo hemopoietic stem cell (HSC) gene therapy approach that involves HSC 
mobilization and intravenous injection of HSC-tropic, integrating HDAd5/35++ vectors. Our studies 
indicate that this approach is safe and effective in rhesus macaques and could be feasible in humans. 
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